COMMUNIQUÉS West-GlobeNewswire

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2025 Financial Results on March 31, 2026
26/03/2026
FREDERICK, Md., March 26, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT [...]
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings
26/03/2026
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ [...]
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
26/03/2026
New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical [...]
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026
26/03/2026
Conférence téléphonique et diffusion en direct sur Internet le mercredi 1er avril 2026 à 14h00 CEST / 8h00 EDT PARIS et CAMBRIDGE, Mass., 26 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – [...]
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
26/03/2026
Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results [...]
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
26/03/2026
LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant [...]
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
26/03/2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ [...]
CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
26/03/2026
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
XORTX Announces Results of Annual and Special Meeting of Shareholders
26/03/2026
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader [...]
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1- [...]
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for [...]
SIGA Declares Special Cash Dividend of $0.60 Per Share
26/03/2026
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0. [...]
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
26/03/2026
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time [...]
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
26/03/2026
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
XORTX Announces Change of Effective Date of Share Consolidation
26/03/2026
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 [...]

Pages